
    
      This is an open label, multi-centre, non-interventional post-marketing surveillance to
      monitor the safety of ALTARGO(retapamulin) treated in Korean patients according to the
      prescribing information.

      ALTARGO is a trademark of the GlaxoSmithKline group of companies.
    
  